Evidence map›Paper›PMID 42012759›Full record

ReviewCurrent atherosclerosis reports2026

Cardiovascular Disease and Dyslipidemia in Pediatric Type 1 Diabetes.

Grace K Kim, Preneet Cheema Brar, Nidhi Bansal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current atherosclerosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Grace K KimDivision of Pediatric Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Preneet Cheema BrarDivision of Pediatric Endocrinology and Diabetes, Department of Pediatrics, New York University Grossman Long Island School of Medicine, New York, NY, USA.
Nidhi BansalDivision of Pediatric Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA. nxbansa1@texaschildrens.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDespite advances in type 1 diabetes (T1D) management, mortality is still increased, with cardiovascular disease (CVD) as the leading cause. Dyslipidemia is a highly prevalent modifiable CVD risk factor. We reviewed the existing literature on CVD mortality in T1D to highlight CVD risk in pediatric patients with T1D. RECENT

findingsPathophysiology of T1D and premature CVD risk is still not fully understood. Dyslipidemia remains a highly prevalent and undertreated CV risk factor in T1D. Statins have been shown to be safe and effective to improve CVD risk in adults with T1D, and in children with familial hypercholesterolemia, in addition to improving lipids levels in children with T1D. T1D is associated with premature CVD mortality, and dyslipidemia is still a highly prevalent and undertreated CVD risk factor. We aim to educate and empower pediatric providers to optimize management of dyslipidemia in pediatric patients with T1D to potentially decrease the CVD risk.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 1DyslipidemiasChildHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular diseaseDyslipidemiaPediatricType 1 diabetes

Identifiers

PMID42012759
PMCPMC13099778

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.